Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 7/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.39 |
| ▸ | CDYL2 | Q8N8U2 | 4/20 | 0.35 |
| ▸ | CDYL | Q9Y232 | 4/20 | 0.35 |
| ▸ | CBX7 | O95931 | 3/20 | 0.35 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 2/20 | 0.35 |
| ▸ | L3MBTL3 | Q96JM7 | 6/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | MBTD1 | Q05BQ5 | 3/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4860518 | 0.90 | CALCRL (0.39) | CALCRLCYP3A4CDYL2CDYLCBX7 | |
| SCHEMBL4860278 | 0.90 | CALCRL (0.39) | CALCRLCYP3A4CDYL2CDYLCBX7 | |
| SCHEMBL4861348 | 0.89 | CALCRL (0.39) | CALCRLCYP3A4CDYL2CDYLCBX7 | |
| SCHEMBL4855630 | 0.88 | CALCRL (0.39) | CALCRLCYP3A4CDYL2CDYLCBX7 | |
| SCHEMBL4858969 | 0.81 | CALCRL (0.40) | CALCRLCYP3A4CDYL2CDYLCBX7 | |
| SCHEMBL6135581 | 0.80 | CALCRL (0.39) | CALCRLCYP3A4CDYL2CDYLCBX7 | |
| SCHEMBL5394689 | 0.77 | CALCRL (0.41) | CALCRLCYP3A4CDYL2CDYLCBX7 | |
| SCHEMBL6798879 | 0.76 | LRRK2 (0.39) | CYP3A4L3MBTL3L3MBTL1MBTD1LRRK2 | |
| SCHEMBL3598608 | 0.74 | PARP1 (0.35) | CALCRLCYP3A4 | |
| SCHEMBL6808411 | 0.73 | PDE3B (0.38) | L3MBTL3L3MBTL1MBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689493-A4 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2008-04-23 | — | — | EP | claimed |
| US-7314883-B2 | Anti-migraine treatments | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-01 | — | — | US | claimed |
| US-20070232600-A1 | ANTI-MIGRAINE TREATMENTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-04 | — | — | US | claimed |
| EP-1689493-A1 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Pharma Company (US) | 2006-08-16 | — | — | EP | claimed |
| WO-2005065779-A1 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-21 | — | — | WO | claimed |
| US-20040204397-A1 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | claimed |
| US-7314883-B2 | Anti-migraine treatments | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-01 | — | — | US | disclosed |
| US-20070232600-A1 | ANTI-MIGRAINE TREATMENTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-04 | — | — | US | disclosed |
| US-20070148093-A1 | Non-terminal method of identifying anti-migraine compounds | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-7220862-B2 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| US-20040204397-A1 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070148093-A1 | Non-terminal method of identifying anti-migraine compounds | VDAC1, HTR3B, FAAH | CALCRL 430/4885CYP3A4 3940/4885CDYL2 2785/4885 |
| US-20070232600-A1 | ANTI-MIGRAINE TREATMENTS | BDKRB2, PTGIR, CALCRL | CALCRL 3/4885CYP3A4 3634/4885CDYL2 4706/4885 |
| US-20040204397-A1 | Calcitonin gene related peptide receptor antagonists | CALCRL, CALCA, CALCR | CALCRL 1/4885CYP3A4 3269/4885CDYL2 4568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.